One is to directly enhance VEGF-B signaling in human chimeric antigen receptor (CAR) T cells for tumor immunotherapy, and the other is to administer VEGF-B–neutralizing antibodies locally in the treatment of T cell–related autoimmune diseases. This evidence concerns the gene VEGFB and autoimmune disease.